Pirlindole hydrochloride is a selective serotonin reuptake inhibitor (SSRI) that has been studied for its potential therapeutic use in treating depression. Its synthesis involves a multi-step process starting from commercially available starting materials. Pirlindole hydrochloride exhibits antidepressant effects by inhibiting the reuptake of serotonin in the brain, thereby increasing serotonin levels. Research on pirlindole hydrochloride aims to understand its efficacy, safety, and potential advantages over existing antidepressants. Its unique pharmacological profile, such as its selectivity for serotonin and its relatively low affinity for other receptors, has sparked interest in its potential therapeutic applications. Studies have shown that pirlindole hydrochloride may have a favorable side effect profile compared to other SSRIs.'
| ID Source | ID |
|---|---|
| PubMed CID | 115141 |
| CHEMBL ID | 1470001 |
| MeSH ID | M0310944 |
| Synonym |
|---|
| 2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino(3,2,1-jk)carbazole monohydrochloride |
| einecs 240-307-9 |
| pirlindon [spanish] |
| pyrazidole |
| 1,10-trimethylene-8-methyl-1,2,3,4-tetrahydropyrazino(1,2-a)indole hydrochloride |
| 1,10-trimethylene-8-methyltetrahydropyrazino(1,2-a)indole hydrochloride |
| pirlindole hydrochloride |
| 2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino(3,2,1j,k)carbazole hydrochloride |
| 1h-pyrazino(3,2,1-jk)carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, monohydrochloride |
| MLS001304023 |
| smr000513888 |
| MLS001204587 |
| MLS001304163 |
| 16154-78-2 |
| D08393 |
| implementor (tn) |
| AKOS005111098 |
| 8-methyl-2,3,3a,4,5,6-hexahydro-1h-pyrazino[3,2,1-jk]carbazole hydrochloride |
| q89w8i397c , |
| pirlindon |
| unii-q89w8i397c |
| 8-methyl-2,3,3a,4,5,6-hexahydro-1h-pyrazino-[3,2,1-jk]carbazole hydrochloride |
| CHEMBL1470001 |
| pirlindole-d4 (deuterated) |
| pirlindole hydrochloride [who-dd] |
| 1h-pyrazino(3,2,1-jk)carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, hydrochloride (1:1) |
| 2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino[3,2,1-jk]carbazole monohydrochloride |
| mfcd00220370 |
| 2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino-[3,2,1-jk]-carbazole hydrochloride |
| 8-methyl-2,3,3a,4,5,6-hexahydro-1h-pyrazino[3,2,1-jk]carbazole hcl |
| 12-methyl-1,4-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-9(16),10(15),11,13-tetraene;hydrochloride |
| Q27287113 |
| 8-methyl-2,3,3a,4,5,6-hexahydro-1h-pyrazino[3,2,1-jk]carbazolehydrochloride |
| CS-0324246 |
| 1h-pyrazino[3,2,1-jk]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl-, hydrochloride (1:1) |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 44.6684 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.9433 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| TDP1 protein | Homo sapiens (human) | Potency | 22.7265 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 70.7946 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 1.9953 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
| geminin | Homo sapiens (human) | Potency | 14.5810 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 7.9433 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||